WatsonR.A., YeungT.M.2011. What is the potential of oligodendrocyte progenitor cells to successfully treat human spinal cord injury?BMC Neurol, 11:113.
2.
Geron Press Release. 2011. http://ir.geron.com/phoenix.zhtml?c=67323&p=irol-newsArticle&ID=1635764&highlight=. 2012 June 19
3.
WirthE.L.J., PriestC., DaviesA., CullenS., DenhamJ., OwensN., SugiantoA., BacoliniL., ReddyA., OkamuraR., LebkowskiJ.2011Abstract for oral presentation at International Spinal Cord Society (ISCoS) 2011 Meeting Abstract number 13http://www.iscos.org.uk/files/Oral%20Presentation%20Abstracts%20from%20the%202011%20International%20Congress%20on%20Spinal%20Cord%20Medicine%20and%20Rehabilitation.pdf. 2012 June 19.
4.
Geron Press Release. 2009. http://ir.geron.com/phoenix.zhtml?c=67323&p=irol-newsArticle&ID=1636192&highlight=. 2012 June 19
5.
JadaszJ., AignerL., RiveraF.J., KuryP.2012. The remyelination Philosopher's Stone: stem and progenitor cell therapies for multiple sclerosis. Cell Tissue Res., 349:331–347.
6.
WindremM.S., NunesM.C., RashbaumW.K., SchwartzT.H., GoodmanR.A., McKhannG.2nd, RoyN.S., GoldmanS.A.2004. Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain. Nat. Med., 10:93–97.
